Ntrk Fusion-positive Solid Tumors

• CLINICAL_TRIALS trial_result · 2026-02-05
  Clinical Trial Update: A Study to Test the Safety of the Investigational Drug Larotrectinib in Adults That May Treat Cancer [Phase 1]

  This update summarizes completion of a Phase 1 trial assessing the safety of larotrectinib in adults with solid tumors harboring NTRK gene f…

• CLINICAL_TRIALS other · 2025-09-11
  Clinical Trial Update: Study of ICP-723 in Patients With Advanced Solid Tumors or Primary Central Nervous System Tumors [Phase 1, Phase 2]

  Clinical trial update for ICP-723 in patients with NTRK fusion-positive advanced solid tumors or NTRK fusion-positive central nervous system…

• FDA approval · 2025-06-11
  FDA Approved: IBTROZI — Original Application (Nuvation Bio Inc.)

  FDA approved IBTROZI (taletrectinib) in an original NDA for NTRK fusion‑positive solid tumors, providing a tumor‑agnostic treatment option.

• CLINICAL_TRIALS trial_result · 2024-10-30
  Clinical Trial Update: A Study to Test the Safety of the Investigational Drug Selitrectinib in Children and Adults That May Treat Cancer [Phase 1]

  Phase 1 safety-focused study update of Selitrectinib in children and adults with NTRK fusion-positive solid tumors. The trial has completed.